Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
about
Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and ManagementThe effects of drugs on human models of emotional processing: an account of antidepressant drug treatmentTargeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic ApproachPostoperative Cognitive Dysfunction: Minding the Gaps in Our Knowledge of a Common Postoperative Complication in the ElderlyEmerging targets for antidepressant therapiesDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsNovel targets for antidepressant therapiesA randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adultsNew therapeutic targets for mood disordersTargeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategyA neurocognitive model for understanding treatment action in depressionBayesian probability of success for clinical trials using historical data.On analysis of longitudinal clinical trials with missing data using reference-based imputation.A role for fMRI in optimizing CNS drug development.Experimental medication treatment approaches for depression.Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndromeNeurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot studyTranslational pharmacokinetics: challenges of an emerging approach to drug development in stroke.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.A pharmacokinetic PET study of NK₁ receptor occupancy.Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.Modelling cognitive affective biases in major depressive disorder using rodents.Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists.Netupitant PET imaging and ADME studies in humans.Involvement of substance P and the NK-1 receptor in human pathology.New targets for rapid antidepressant action.Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.G protein-coupled receptors in major psychiatric disorders.Neuroimaging in psychiatric disordersBehavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists.Novel drugs and therapeutic targets for severe mood disorders.Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral painThe interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.Quantification of central substance P receptor occupancy by aprepitant using small animal positron emission tomography.Translational and reverse translational research on the role of stress in drug craving and relapse.Aprepitant and fosaprepitant: a 10-year review of efficacy and safetySubstance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells.Advances in the Management of Treatment-Resistant Depression
P2860
Q26751458-0D4F7250-6BB7-4464-9944-48AFCDBF828DQ28072345-546D16A5-E69F-4C08-8891-6D884996D6B2Q28085005-DD0C4107-F8E7-4207-A6E0-F10599D97828Q28086981-7DC7944B-C767-4CE6-8B0C-DF7F156724F1Q28247614-15DF97CF-D08B-40B0-BABD-6ECF97FF08ABQ28305100-F7912B73-332F-4328-AAB2-CCC9CCAEAA93Q28648254-0A63B05D-DE09-4EEC-97AE-73E9FFBE229CQ28740565-BFD7C317-64CE-4114-917E-3C8C13162471Q28743068-99BD4C2E-6662-4D51-A04A-8570BAF627C5Q28751738-5E0D5E4A-EFBF-46D8-949F-A50F74921977Q30374324-E9B7DD9A-E92B-4062-AF65-3A136CC9D359Q30863734-B48A6A2A-AF63-40F0-812F-543C8DAE0FBEQ30998995-343B361B-64C2-47EF-B564-3201CCC3FE5EQ31036354-343B7709-8E87-45DF-B5B8-C65DD442A507Q33635577-1965ED42-3A35-441E-A52D-4DD0D5DC0AAAQ33752757-AB2C3E27-CE00-4C81-A0FE-51261A745043Q33815691-63879AE4-CDCB-42E4-A3B7-22F444A3E10CQ33882182-FE40A41E-8398-472A-8BD9-9C3C9298843EQ34157073-45AFFE68-3984-480C-A96F-613051272C81Q34223613-87BE8C76-B80B-4DD0-9518-091D8B316799Q34275762-58DB1348-4038-46A4-9E81-DCAFC0F468EBQ34335917-A10BCE3F-1AF3-41A1-84E5-650A691EDC22Q34349717-673E7D05-0F38-446D-A128-9C488312FFEAQ34376340-44458A3C-6359-4169-A1CA-BB94BA719A4AQ34377521-868E1A04-E762-430E-A6BF-9F350273B821Q34413850-46266E79-016F-4C6B-BD8F-A4BABB82C821Q34507177-861E397E-EE33-43F8-8786-3D5694938B3CQ34512818-D88D89E0-F4C1-4359-9028-6442BAF4686BQ34578414-53AD6BEE-BF6C-410E-8B47-D270CCCA69B7Q34644697-64EB03C5-5FD9-4AD0-B929-CDFBF1282599Q34697510-79A216DE-B45A-4DCC-BDA9-4FA133D97395Q34732759-2A0B2635-309C-4F6D-B971-8D7F674A6771Q34766451-6A0CB868-C737-4068-B3CD-1CACDDA193CBQ34954885-03F2BF77-501C-477D-A070-DDB81E883229Q35137131-7DDFFEF8-7701-4476-A6CB-088056BDB03AQ35203652-6FA78B5C-64F2-41A0-8E65-8F65E5E0B021Q35332832-5AD17DBC-9FEA-4D79-99D4-CB5795662FD3Q35345557-8F3B8117-DAAD-4FE8-A8E0-D065AAA9D5D0Q35538215-0CD7B82F-ADDC-4213-A463-91301CA56948Q35580600-8BF398CA-6A24-4D17-B739-2E9A4D9002B3
P2860
Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Lack of efficacy of the substa ...... of major depressive disorder.
@ast
Lack of efficacy of the substa ...... of major depressive disorder.
@en
Lack of efficacy of the substance p
@nl
type
label
Lack of efficacy of the substa ...... of major depressive disorder.
@ast
Lack of efficacy of the substa ...... of major depressive disorder.
@en
Lack of efficacy of the substance p
@nl
prefLabel
Lack of efficacy of the substa ...... of major depressive disorder.
@ast
Lack of efficacy of the substa ...... of major depressive disorder.
@en
Lack of efficacy of the substance p
@nl
P2093
P1476
Lack of efficacy of the substa ...... of major depressive disorder.
@en
P2093
Christopher Lines
Duane Snavely
Guanghan Liu
Jarmo Hietala
Katherine Beebe
Martin Keller
Mary Morrison
Richard Hargreaves
Scott Reines
Stuart Montgomery
P304
P356
10.1016/J.BIOPSYCH.2005.07.013
P407
P577
2005-10-24T00:00:00Z